Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda Pharmaceutical : Exkivity Wins FDA Approval for Treatment of Lung Cancer with EGFR Exon 20 Insertion Mutation

09/15/2021 | 05:02pm EDT


ę MT Newswires 2021
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
10/14TAKEDA PHARMACEUTICAL : Working With Immusoft to Develop B-Cell Therapies for Rare Neurome..
MT
10/13TR1 : Notification of Major Shareholding
DJ
10/13TAKEDA PHARMACEUTICAL : BioLife Plasma Services Announces Expansion of Plasma Donation Cen..
BU
10/13Immusoft and Takeda Pharmaceutical Company Limited Collaborate to Discover and Develop ..
CI
10/12POSEIDA THERAPEUTICS : Takeda to Jointly Develop Novel Non-Viral In Vivo Gene Therapies
MT
10/12Poseida Therapeutics, Inc. Announces Research Collaboration with Takeda Pharmaceutical ..
CI
10/12Poseida Therapeutics, Takeda Pharmaceutical in Research, License Pact
DJ
10/08TAKEDA PHARMACEUTICAL : - FDA Advisory Committee Recommends Use of Investigational Drug Ma..
AQ
10/08TAKEDA PHARMACEUTICAL : Says FDA Panel Backs Use of Maribavir as Potential Treatment for C..
MT
10/08TAKEDA PHARMACEUTICAL : NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART,..
PU
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 383 B 29 612 M 29 612 M
Net income 2022 252 B 2 202 M 2 202 M
Net Debt 2022 3 258 B 28 510 M 28 510 M
P/E ratio 2022 20,4x
Yield 2022 5,57%
Capitalization 5 082 B 44 517 M 44 481 M
EV / Sales 2022 2,46x
EV / Sales 2023 2,33x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Last Close Price 3 232,00 JPY
Average target price 4 551,43 JPY
Spread / Average Target 40,8%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED-13.93%44 517
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.13.20%232 621
ELI LILLY AND COMPANY40.89%215 657